The shares of Rallybio Corporation (NASDAQ: RLYB) are experiencing a remarkable surge in today’s trading, marking a notable increase of 71.73% to achieve $2.80 as of the last check in the current session. The announcement of a collaborative partnership targeted at improving medicinal treatments preceded this increase in RLYB shares.
Rallybio (RLYB) has disclosed a partnership with Johnson & Johnson to bolster the development of complementary therapeutic strategies aimed at mitigating the risk of fetal and neonatal alloimmune thrombocytopenia (FNAIT). Moreover, Rallybio has secured an equity investment totaling $6.6 million from Johnson & Johnson Innovation – JJDC, Inc.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
Rallybio is in the process of advancing RLYB212, an innovative human monoclonal anti-HPA-1a antibody meticulously crafted to forestall alloimmunization among pregnant individuals, thereby averting the peril of FNAIT and its potentially catastrophic ramifications on their offspring. Rallybio is set to commence a Phase 2 dose validation study for RLYB212 in pregnant individuals deemed to be at higher risk of alloimmunization and FNAIT in the latter half of 2024.
As part of this collaboration, Johnson & Johnson will extend financial support to Rallybio to raise awareness about Johnson & Johnson’s FNAIT clinical program in conjunction with Rallybio’s ongoing FNAIT natural history study. Rallybio stands to receive additional payments under the terms of this collaboration.
RLYB212 represents the sole investigational therapy currently known to be undergoing clinical development to address the needs of pregnant individuals at risk of FNAIT who have not undergone alloimmunization. Meanwhile, Johnson & Johnson is spearheading a Phase 3 study of nipocalimab, an investigational monoclonal antibody targeting FcRn, in pregnant individuals who have already undergone alloimmunization.
Given that these individuals harbor the alloantibodies that can trigger FNAIT, prophylactic treatment with RLYB212 would be deemed inappropriate. Rallybio’s complementary approaches are believed to ensure that pregnant individuals susceptible to developing FNAIT have a potential treatment avenue available to them – irrespective of their alloimmunization status.
Collaborating with Johnson & Johnson Innovation, Rallybio can better and more swiftly foster awareness of FNAIT, underscore the significance of screening pregnant individuals for their FNAIT risk, and advance its complementary therapeutic strategies.
